Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArtivionAORT +5.84%81 14-Day RSI is 62.20 as of Jul. 17, 2026. GuruFocus rates AORT with a GF Score™ of 81/100 and a GF Value™ of $28.44 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Artivion ranks worse than 86.18% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-17), Artivion's 14-Day RSI is 62.20.
The industry rank for Artivion's 14-Day RSI or its related term are showing as below:
AORT's 14-Day RSI is ranked worse than 86.18% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 49.005
vs AORT: 62.20
Artivion (NYSE:AORT) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Artivion 14-Day RSI Related Terms
AORT vs LMRI, AVNS, TNDM: 14-Day RSI Comparison
For the Medical Devices subindustry, Artivion's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artivion 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Artivion's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Artivion's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artivion (AORT) has a 14-Day RSI of 62.20 as of Jul. 17, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Artivion and its competitors. According to the industry distribution chart, Artivion ranks #748 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 86.2%.
Is Artivion's 14-Day RSI too high?
Artivion's current 14-Day RSI is 62.20. The Medical Devices & Instruments industry median 14-Day RSI is 49.01. Artivion's value of 62.20 is 26.9% above this industry median. Based on the distribution chart, Artivion ranks #748 out of 868 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Artivion has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Artivion's 14-Day RSI compare to LMRI and AVNS?
According to the Medical Devices & Instruments industry distribution chart, Artivion ranks #748 out of 868 companies for 14-Day RSI. This places Artivion in the lower half of its industry. The industry median 14-Day RSI is 49.01. Artivion's value of 62.20 is 26.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 49.01, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artivion's current 14-Day RSI of 62.20 is 26.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Artivion and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 49.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artivion's current 14-Day RSI is 62.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artivion stock overvalued right now?
Based on GuruFocus' analysis, Artivion (AORT) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.44, compared to a current price of $25.73 — trading 9.5% below its estimated fair value. The current 14-Day RSI is 62.20 and 26.9% above the Medical Devices & Instruments industry median of 49.01. Artivion's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Artivion (AORT), the current 14-Day RSI is 62.20 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artivion (AORT) Overvalued in 2026?
Based on GuruFocus' analysis, Artivion stock appears to be undervalued.
The current stock price of $25.73 is trading 9.5% below its estimated GF Value™ of $28.44.
GuruFocus considers Artivion to be Modestly Undervalued.
Key valuation signals for AORT:
14-Day RSI: 62.20
GF Value™: $28.44 vs. price of $25.73 (9.5% below fair value)
Industry Position: 26.9% above the Medical Devices & Instruments median (#748 of 868)
No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
81GF Score
Get the complete analysis for AORT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AORT has been successfully added to your 
